Anti-TB Drug Pretomanid

July 24, 2020

Drugs Controller General of India (DCGI) has approved anti-tuberculosis drug pretomanid for conditional access under the **National Tuberculosis Elimination Programme.** Pretomanid has been developed by **non-profit organisation TB Alliance.**

Anti-TB Drug Pretomanid

It is part of a **3-drug, 6-month, all-oral regimen for treatment of pulmonary extensively drug-resistant TB and non-responsive multi drug-resistant TB.** Pretomanid is an investigational tuberculosis (TB) drug developed by TB Alliance for **use in combination with bedaquiline and linezolid** for treating a limited and specific population of adult patients with extensively drug-resistant, treatment-intolerant or non-responsive multidrug-resistant pulmonary TB.

Pretomanid is a new chemical entity and a **member of a class of compounds known as nitroimidazooxazines.** Novel compounds are important in pursuing new TB treatments because **resistance to drugs and drug classes currently used to treat TB is widespread.** It was developed as an oral tablet formulation for the treatment of tuberculosis in combination with other anti-tuberculosis agents. One such combination is BPaL (bedaquiline + pretomanid + linezolid).

Current therapy for drug-resistant TB often requires people to take drugs for 6 months to 2 years or longer—or risk developing more difficult to treat drug-resistant TB. The WHO reports historical treatment success for XDR-TB at about 34%. BPaL has been tested in drug-resistant TB patients co-infected with HIV, including those receiving antiretrovirals (ARVs).

Pretomanid Tablets are not indicated for patients with:

- Drug-sensitive (DS) tuberculosis

- Latent infection due to Mycobacterium tuberculosis
- Extra-pulmonary infection due to Mycobacterium tuberculosis
- MDR-TB that is not treatment-intolerant or non-responsive to standard therapy